The content of this presentation is provided to an audience of international healthcare professionals for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

The American Heart Association
Scientific Sessions 2023 11-13 November 2023

Scientific publications at AHA Scientific Sessions 2023.

Thank you for your interest! Please see below to download the posters/presentations at AHA 2023. Presentations, Videos and Posters will be available following the presentation at the congress.

Some of the links to view the Presentations or Posters will link to the official AHA 2023 web page. You may need to be a registered delegate and logged in the respective platform to view the content.

Finerenone

Nov 12, 2023 9:45 AM - 11:00 AM
Impact of finerenone on cardiac biomarkers in patients with T2D and chronic kidney disease

Session: Cardiovascular Disease in Chronic Kidney Disease: New Horizons from the Bench to Bedside Lead author: Mario Berger

Doc Icon

Download the Slide Deck

Nov 13, 2023 10:30 AM – 11:45 AM PM  
Steroidal mineralocorticoid receptor antagonist treatment patterns and predictors of discontinuation

Session: Skipping a Beat: Challenges in Cardiovascular Medication Adherence

Lead Author: Emma Richard

Doc Icon

Download the Slide Deck
Finerenone: a new approach to kidney protection in patients with type 2 diabetes


Saturday 17 June, 2023 | 13.35 - 13.45 CET | On Demand
Non-steroidal MRAs: A new pillar of treatment for cardiorenal protection in CKD and T2D
The symposium offers a unique opportunity to gain an overview of the most recent guideline updates related to CKD and T2D and the need for a comprehensive and holistic approach to the patient management. To discuss the use of the ‘pillar approach’ to manage CKD in T2D and how to use finerenone in clinical practice based on expert experience. To highlight the relevance of the urgency to treat CKD in T2D to improve cardiorenal outcomes.

Faculty: Giuseppe Grandaliano (chair), Beatriz Fernandez, Christoph Wanner, Rajiv Agarwal Session: Industry Sponsored Symposium Speaker: Rajiv Agarwal

Play Icon

View Video

17/06/2023 - 8:30 - 9:45 CEST

FINEGUST- Japan; characteristics of medication-initiator cohorts of patients with chronic kidney disease and type 2 diabetes in Japan - a report from FOUNTAIN platform

Session type: focused oral presentation ROOM 6 Presenter: Yuichiro Yano

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

16/06/2023 - 08:30-09:45 CEST

Validation of a CKD progression risk prediction model in the FIDELITY trial population

Session type: poster / abstract Presenter: Navdeep Tangri

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

17/06/2023 - 14:45 - 16:00 CEST

REKA: Incidence and frequencies of hyperkalemia in patients with chronic kidney disease: a retrospective database study from US clinical care

Session type: focused oral presentation ROOM 1 Presenter: Van Boemmel-Wegmann

Play Icon

Visit Link to View Video
Doc Icon

Download the Slide Deck

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from the American Heart Association (AHA) and from the authors.

 

© 2023 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

  • MA-M_FIN-ALL-1473-1

Last updated on 26/10/2023